受体相互作用蛋白激酶1（RIPK1）抑制剂作为多种炎症性和神经退行性疾病的潜在治疗方法。
Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors as Potential Treatment for Several Inflammatory and Neurodegenerative Diseases.
作者信息
Abdel-Magid Ahmed F
机构信息
PI Health Sciences, 100 Jade Park, Chelsea, Alabama 35043, United States.
出版信息
ACS Med Chem Lett. 2025 Jan 27;16(2):204-206. doi: 10.1021/acsmedchemlett.5c00026. eCollection 2025 Feb 13.
The invention in this patent application relates to 2-amino-[1,2,4]triazolo[1,5-]pyridin derivatives represented generally herein as formula 1. These compounds have activities as receptor-interacting protein kinase 1 (RIPK1) inhibitors and may potentially provide treatment and/or prophylaxis of inflammatory and neurodegenerative diseases associated with aberrant RIPK1 activity such as ulcerative colitis, Crohn's disease, psoriasis, NASH, heart failure, multiple sclerosis, amyotrophic lateral sclerosis (ALS), and Alzheimer's disease.
本专利申请中的发明涉及本文一般表示为式1的2-氨基-[1,2,4]三唑并[1,5-a]吡啶衍生物。这些化合物具有作为受体相互作用蛋白激酶1（RIPK1）抑制剂的活性，并可能潜在地提供与异常RIPK1活性相关的炎性和神经退行性疾病的治疗和/或预防，例如溃疡性结肠炎、克罗恩病、银屑病、非酒精性脂肪性肝炎、心力衰竭、多发性硬化症、肌萎缩侧索硬化症（ALS）和阿尔茨海默病。
Zotero 插件